|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas N: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Greenman C, Stephens P, Smith R, Dalgliesh
GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C,
et al: Patterns of somatic mutation in human cancer genomes.
Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nik-Zainal S, Alexandrov LB, Wedge DC, Van
Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J,
Stebbings LA, et al: Mutational processes molding the genomes of 21
breast cancers. Cell. 149:979–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smith HC, Bennett RP, Kizilyer A,
McDougall WM and Prohaska KM: Functions and regulation of the
APOBEC family of proteins. Semin Cell Dev Biol. 23:258–268. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Refsland EW and Harris RS: The APOBEC3
family of retroelement restriction factors. Curr Top Microbiol
Immunol. 371:1–27. 2013.PubMed/NCBI
|
|
11
|
Harris RS and Liddament MT: Retroviral
restriction by APOBEC proteins. Nat Rev Immunol. 4:868–877. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ng JCF, Quist J, Grigoriadis A, Malim MH
and Fraternali F: Pan-cancer transcriptomic analysis dissects
immune and proliferative functions of APOBEC3 cytidine deaminases.
Nucleic Acids Res. 47:1178–1194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang S, Jia M, He Z and Liu XS: APOBEC3B
and APOBEC mutational signature as potential predictive markers for
immunotherapy response in non-small cell lung cancer. Oncogene.
37:3924–3936. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wen WX, Soo JS, Kwan PY, Hong E, Khang TF,
Mariapun S, Lee CS, Hasan SN, Rajadurai P, Yip CH, et al: Germline
APOBEC3B deletion is associated with breast cancer risk in an Asian
multi-ethnic cohort and with immune cell presentation. Breast
Cancer Res. 18:562016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Burns MB, Lackey L, Carpenter MA, Rathore
A, Land AM, Leonard B, Refsland EW, Refsland EW, Kotandeniya D,
Tretyakova N, et al: APOBEC3B is an enzymatic source of mutation in
breast cancer. Nature. 494:366–370. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Middlebrooks CD, Banday AR, Matsuda K,
Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S,
Kubo M, et al: Association of germline variants in the APOBEC3
region with cancer risk and enrichment with APOBEC-signature
mutations in tumors. Nat Genet. 48:1330–1338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roberts SA, Lawrence MS, Klimczak LJ,
Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL,
Saksena G, et al: An APOBEC cytidine deaminase mutagenesis pattern
is widespread in human cancers. Nat Genet. 45:970–976. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harris RS: Molecular mechanism and
clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer.
Breast Cancer Res. 17:82015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Delahanty R, Guo X, Zheng W and
Long J: Integrative genomic analysis reveals functional
diversification of APOBEC gene family in breast cancer. Hum
Genomics. 9:342015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kuong KJ and Loeb LA: APOBEC3B mutagenesis
in cancer. Nat Genet. 45:964–965. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanu N, Cerone MA, Goh G, Zalmas LP,
Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I,
et al: DNA replication stress mediates APOBEC3 family mutagenesis
in breast cancer. Genome Biol. 17:1852016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cescon DW, Haibe-Kains B and Mak TW:
APOBEC3B expression in breast cancer reflects cellular
proliferation, while a deletion polymorphism is associated with
immune activation. Proc Natl Acad Sci USA. 112:2841–2846. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sieuwerts AM, Willis S, Burns MB, Look MP,
Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels
L, Leyland-Jones B, et al: Elevated APOBEC3B correlates with poor
outcomes for estrogen-receptor positive breast cancers. Horm
Cancer. 5:405–413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsuboi M, Yamane A, Horiguchi J, Yokobori
T, Kawabata-Iwakawa R, Yoshiyama S, Rokudai S, Odawara H, Tokiniwa
H, Oyama T, et al: APOBEC3B high expression status is associated
with aggressive phenotype in Japanese breast cancers. Breast
Cancer. 23:780–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Law EK, Sieuwerts AM, LaPara K, Leonard B,
Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME,
Sweep FC, et al: The DNA cytosine deaminase APOBEC3B promotes
tamoxifen resistance in ER-positive breast cancer. Sci Adv.
2:e16017372016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rüder U, Denkert C, Kunze CA, Jank P,
Lindner J, Jöhrens K, Kulbe H, Sehouli J, Dietel M, Braicu E and
Darb-Esfahani S: APOBEC3B protein expression and mRNA analyses in
patients with high-grade serous ovarian carcinoma. Histol
Histopathol. 34:405–417. 2018.PubMed/NCBI
|
|
27
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th. Springer
(ed.); New York: pp. 345–376. 2010
|
|
28
|
Chang W, Gao X, Han Y, Du Y, Liu Q, Wang
L, Tan X, Zhang Q, Liu Y, Zhu Y, et al: Gene expression
profling-derived immunohistochemistry signature with high
prognostic value in colorectal carcinoma. Gut. 63:1457–1467. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao XH, Liu QZ, Chang W, Xu XD, Du Y, Han
Y, Liu Y, Yu ZQ, Zuo ZG, Xing JJ, et al: Expression of ZNF148 in
diferent developing stages of colorectal cancer and its prognostic
value: A large Chinese study based on tissue microarray. Cancer.
119:2212–2222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salgado R, Denkert C, Demaria S, Sirtaine
N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL,
Penault-Llorca F, et al: The evaluation of tumor-infiltrating
lymphocytes (TILs) in breast cancer: Recommendations by an
International TILs Working Group 2014. Ann Oncol. 26:259–271. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li B, Severson E, Pignon JC, Zhao H, Li T,
Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive
analyses of tumor immunity: Implications for cancer immunotherapy.
Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Du Y, Tao X, Wu J, Yu H, Yu Y and Zhao H:
APOBEC3B up-regulation independently predicts ovarian cancer
prognosis: A cohort study. Cancer Cell Int. 18:782018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fujiki Y, Yamamoto Y, Sueta A,
Yamamoto-Ibusuki M, Goto-Yamaguchi L, Tomiguchi M, Takeshita T and
Iwase H: APOBEC3B gene expression as a novel predictive factor for
pathological complete response to neoadjuvant chemotherapy in
breast cancer. Oncotarget. 9:30513–30526. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao Y, Qu Q, Chen X, Huang O, Wu J and
Shen K: The Prognostic value of tumor-infiltrating lymphocytes in
breast cancer: A Systematic review and meta-analysis. PLoS One.
11:e01525002016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mao Y, Qu Q, Zhang Y, Liu J, Chen X and
Shen K: The value of tumor infiltrating lymphocytes for predicting
response to neoadjuvant chemotherapy in breast cancer: A systemic
review and meta-analysis. PLoS One. 9:e01151032014. View Article : Google Scholar
|
